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The present study was aimed at investigating the eﬃcacy and mechanism(s) of action of a Chinese herbal formulation, Liuwei
Dihuang (LWDH), as a prospective natural weight-lowering product. Following a 2-week acclimation period, 48 obesity-prone
(OP-CD) rats were divided into 4 groups (n = 12 each). One group served as a positive control for obesity (OP), while the other
3 were challenged twice daily by oral gavage with total daily dosages of 500, 1500, or 3500mg/kg BW LWDH, respectively, for
10 weeks. One group (n = 12) of obesity-resistant (OR-CD) rats served as the normal control group. All rats were fed the same
AIN-93G diet modiﬁed to contain 60% energy from fat. The highest LWDH dose signiﬁcantly reduced body weight during the last
4 weeks of treatment. Food intake was reduced beginning in week 2. The high LWDH dose lowered serum triglyceride (TG) and
nonesteriﬁed fatty acid (NEFA) levels and body fat. Both the high and medium doses also lowered serum leptin and insulin levels.
Liver function testing revealed no adverse side eﬀects under the current experimental conditions. The results of the present study
suggest that LWDH has potential as a preventive or therapeutic natural product against overweight and obesity.
1.Introduction
The obesity epidemic is no longer limited to the developed
countries but is now also rapidly spreading to developing
countries [1,2].Associatedwithoverweightandobesityisan
increased risk for the development of cardiovascular disease
(CVD), type 2 diabetes mellitus (T2DM), hypertension, dys-
lipidemia, and other complications [3]. The rapidly increas-
ing prevalence of obesity has been negatively inﬂuencing the
quality of human life and imposing an enormous burden on
the health care system. Thus, control of body weight has now
become one of the top priorities in nutritional and medical
research. Studies have shown that a reduction of 5–10%
body weight is suﬃcient to signiﬁcantly improve many of the
knownobesity-relatedbloodbiochemistryparameters[4,5],
including hyperlipidemia, insulin and leptin resistance, and
increased circulating nonesteriﬁed fatty acids (NEFA) [4–7].
Leptin and insulin play a critical role in energy home-
ostasis [8]. These two hormones can relay information about
p e r i p h e r a lf a ts t o r e st ot h eb r a i n[ 9], by converging on
speciﬁc neurons in the hypothalamus [10] and modulating
eating behaviour and energy expenditure [11, 12]. One
key feature of obesity is the development of insulin and
leptin resistance [13, 14], resulting in an elevation of the
circulating levels of these two hormones as a consequence
of compensatory physiological responses to insulin and
leptin insensitivity [13, 15]. With the onset of insulin and
leptin resistance, changes occur in several other obesity-
related blood biomarkers, such as an increase in NEFA and
triglyceride (TG) levels in the circulation, as well as in the
liver and muscle tissues [16].
To date, lifestyle changes, including dietary habits and
exercise, remain the primary intervention for weight loss or
control. However, long-term compliance has challenged its2 Evidence-Based Complementary and Alternative Medicine
eﬀectiveness. Diﬀerent from other health problems and dis-
eases, few dietary supplements or drugs have been successful
in the prevention or treatment of obesity [17]. As a result,
there exists a strong demand to continue searching for both
safe and eﬃcacious products to combat this emerging health
epidemic. Traditional Chinese medicine (TCM) has been
considered to have huge potential as an information source
and starting point for the development of antiobesity prod-
ucts. The ancient TCM Liuwei Dihuang (LWDH), prepared
fromabasicformulaofsixChineseherbs(RadixRehmanniae
Preparata, RRP; Rhizoma Dioscoreae,R D ;Fructus Corni,F C ;
Cortex Moutan,C M ;Rhizoma Alismatis,R A ;Poria)[ 18, 19],
is widely produced in China in accordance with the China
Pharmacopoeia standard of quality control [20]. Despite
its worldwide use for general health promotion [21], little
is known about its potential beneﬁts in regards to energy
homeostasis and weight management.
The aim of the present study was to evaluate the antiobe-
sity eﬀects of the Chinese herbal formulation, LWDH, by
measuring body weight, food intake, body fat mass, blood
lipidproﬁles,andthehormonesleptinandinsulinusingarat
model of obesity. In order to evaluate potential toxicity, liver
function testing was performed by analysing serum levels of
the liver enzymes aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (ALP), and γ-
glutamyltransferase (GGT).
2.MaterialsandMethods
2.1. Animals and Diet. Sixty male CD rats were pur-
chased from Charles River Laboratories (Montr´ eal, Qu´ ebec,
Canada). Twelve of these animals were of the obesity-
resistant strain (OR-CD), and 48 were of the obesity-prone
strain (OP-CD). All animals were housed individually in
cages in a temperature controlled room with a 12-hour
light:darkcycle.Followinga2-weekacclimationperiodwith
free access to regular rodent chow and water, the average
body weight became 263 ± 21g for the OR-CD rats and
300 ± 19g for the OP-CD rats. The OR-CD rats served as
the normal control group (OR), and the OP-CD rats were
randomly divided into 4 groups (n = 12 each) prior to
the commencement of treatment. One group of OP-CD rats
served as the obesity control (OP), while the other 3 (T1A,
T1B, and T1C) were treated for 10 weeks by twice daily oral
gavage with total daily dosages of 500, 1500, or 3500mg/kg
BWoftheconcentratedLWDHpills(WanxiPharmaceuticals
Co. Ltd., Henan, China) dissolved in water. The OR and OP
control groups received water via oral gavage as the control
vehicle. The gavage method was chosen versus adding to the
diet in order to ensure dosage control. In addition to proper
training, gavage feeding was optimized by using soft plastic
gavage tubing, which produces much less stress than typical
gavage needles. Treatment administration was performed
during the light cycle, once in the morning and again 6
hours later. Throughout the treatment period, all rats were
fed the AIN-93G diet modiﬁed to contain 60% energy from
fat(lard:sunﬂoweroil(96:4,wt/wt)).Bodyweightandfood
intake were recorded on a daily basis. At the end of the study,
all animals were anaesthetized using Isoﬂurane (Abraxis
BioScience, Richmond Hill, Ontario, Canada) following
an overnight fast. Blood samples were collected via left
ventricular cardiac puncture, placed on ice, and allowed to
clot. After centrifugation, serum was collected, aliquoted,
a n ds t o r e da t−80◦C until analysis of each biomarker within
a short period of time. Epididymal, perirenal, and omental
fat depots were weighed and recorded, and the total body
fat mass of the 3 portions was calculated. The animal use
and experimental protocols were approved by the Joint
Animal Care and Research Ethics Committee of the National
Research Council Canada and the University of Prince
Edward Island. The study was conducted in accordance with
the guidelines of the Canadian Council on Animal Care.
2.2. Preparation and Dose Consideration of Concentrated
LWDH Pills. The LWDH-concentrated pills used in the
present study were manufactured by Henan Wanxi Phar-
maceuticals Ltd. Co. (Nanyang, Henan, China) using the
six Chinese herbs at a composition of 160g RRP, 80g RD,
80g FC, 60g CM, 60g RA, and 60g Poria. Brieﬂy, following
extraction with 95% ethanol, the residue of CM was mixed
with all RRP, RA and Poria, and part of FC (27g), followed
by extraction with hot water (twice, 2hr each). The water
extract was then concentrated to form a paste and mixed
with powdered RD and FC (53g), and the ethanol extract of
CM to form the ﬁnal product. Based on the recommended
daily human dosage of 24 pills (approximately 4.5g/d), and
the previously reported dosage of 2.4g/kg/d in rats [22], 3
dosages of 500, 1500, or 3500mg/kg BW were chosen in the
present study.
2.3. Measurement of Serum Lipids. Lipid levels in the serum,
including total cholesterol (T-C), TG, and HDL-cholesterol
(HDL-C) were measured in duplicate using the TC Matrix
Biochemistry Analyzer (Teco Diagnostics, Anaheim, Calif,
USA) and supplied reagents. Non-HDL-C levels were calcu-
lated by subtracting HDL-C from T-C [23].
2.4. Measurement of Serum Nonesteriﬁed Fatty Acids. Serum
NEFA levels were measured in duplicate using commercial
kits (BioVision Research Products, Mountain View, Calif,
USA), in accordance with the kit instructions. Standards
were prepared at a series of concentrations and run in
parallel with the samples. The levels of NEFA were calculated
in reference to the corresponding standard curves and
expressed as nmol/μL.
2.5.MeasurementofSerumInsulinandLeptin. Seruminsulin
and leptin levels were quantiﬁed in duplicate using com-
mercial ELISA kits (Crystal Chem Inc., Downer’s Grove,
Ill, USA). Each assay was performed following the kit
instructions. Standards at a series of concentrations were
run in parallel with the samples. The insulin and leptin
concentrations in the samples were calculated in reference to
the corresponding standard curves and expressed as ng/mL.
2.6. Measurement of Liver Enzymes in the Serum. Liver
enzyme levels in the serum, including AST, ALT, ALP, andEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: LWDH signiﬁcantly lowered body weight in obese
rats. OR: obesity-resistant normal control; OP: obesity-prone
positive control; T1A, T1B, and T1C represent the 3 obesity-
prone groups treated by twice daily oral gavage with total daily
dosages of 500, 1500, or 3500mg/kg BW of the LWDH herbal
formulation, respectively. All animals were fed a high-fat diet (AIN-
93G diet modiﬁed to contain 60% energy from fat (lard:sunﬂower
oil (96:4, wt/wt)). Data were analyzed by one-way ANOVA.
Diﬀerencesbetweentreatmentmeansweredeterminedbypair-wise
comparisons using the least squares means test, with P<0.05
indicating statistical signiﬁcance. Results are presented as mean
values with their standard errors (n = 12). ∗Diﬀered signiﬁcantly
from OP (P<0.05).
GGT, were measured in duplicate using enzymatic methods
on the TC Matrix Biochemistry Analyzer (Teco Diagnostics,
Anaheim, Calif, USA) and supplied reagents.
2.7. Statistical Analysis. Data analyses were performed by
one-way ANOVA using SAS 9.2 statistical software (SAS
Institute, NC, USA). Diﬀerences between treatment means
were determined by pair-wise comparisons using the least
squares means test, with P<0.05 indicating statistical
signiﬁcance. Results are presented as mean values with their
standard errors.
3. Results
3.1. LWDH Signiﬁcantly Lowered Body Weight in Obese Rats.
Throughout the 10-week treatment period, rats in the T1C
group had signiﬁcantly lower (P<0.05) body weights
compared to the obesity control OP rats (Figure 1). A
signiﬁcant body weight reduction in the TIC group was
detected at week 7. This was further highlighted by a ﬁnal
body weight reduction of 8% compared to the OP rats,
beginning at week 8 and persisting until the end of the study.
The T1B group had a tendency towards reduced body weight
butdidnotreachstatisticalsigniﬁcance,whiletheT1Agroup
showed no eﬀect.
3.2. Eﬀe c to fL W D Ho nB o d yF a tC o m p o s i t i o ni nO b e s eR a t s .
To determine the eﬀe c to fL W D Ho nb o d yf a tm a s sa n d
composition, epididymal, perirenal, and omental fat samples
were excised and weighed. After the 10-week treatment
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Figure 2: Lipid-lowering eﬀects of LWDH in obese rats. OR:
obesity-resistant normal control; OP: obesity-prone positive con-
trol; T1A, T1B, and T1C represent the 3 obesity-prone groups
treated by twice daily oral gavage with total daily dosages of
500, 1500, or 3500mg/kg BW of the LWDH herbal formulation,
respectively. All animals were fed a high-fat diet (AIN-93G diet
modiﬁed to contain 60% energy from fat (lard:sunﬂower oil
(96:4,wt/wt)). Data were analyzed by one-way ANOVA. Diﬀer-
ences between treatment means were determined by pair-wise
comparisons using the least squares means test, with P < 0.05
indicating statistical signiﬁcance. Results are presented as mean
values with their standard errors (n = 12). ∗Diﬀered signiﬁcantly
from OP (P<0.05).
period, rats in the T1C group showed signiﬁcantly less (P<
0.05) fat mass in these regions compared to the OP control
rats (Table 1). This observation was also noted in the total fat
mass of the 3 portions.
3.3. Eﬀect of LWDH on Weekly Food Intake in Obese Rats.
During the ﬁrst week of treatment, food intake was not
aﬀected. After 2 weeks, rats in the T1C group had reduced
(P<0.05) food intake compared to the OP controls,
with this observation being noted until the end of the
study (Table 2). Group T1B also showed a tendency towards
decreased food intake, with signiﬁcant reductions (P<
0.05) during weeks 3 and 4 compared to the OP control.
Group T1A did not show any signiﬁcant eﬀect. A signiﬁcant
correlation was detected between food intake and body
weight (r = 0.7094, P<0.001).
3.4. Lipid-Lowering Eﬀects of LWDH in Obese Rats. At the
end of the study, the T1C group showed a 28% reduction
(P<0.05) in serum TG levels compared to the OP control.
Serum T-C levels in the T1C group were reduced by 11%
but did not reach statistical signiﬁcance (P = 0.13) when
comparedtothe OPcontrol,dueto largevariations observed
within the group (Figure 2). The levels of serum HDL-C and
non-HDL-C in each of the LWDH treatment groups did not
diﬀer from the OP control.
3.5. LWDH Signiﬁcantly Lowered Serum Nonesteriﬁed Fatty
Acids in Obese Rats. Compared to the OP control, rats in the
T1C group had signiﬁcantly lower (P<0.05) NEFA levels
(Figure 3). In addition, the T1B group had marginally lower4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀe c to fL W D Ho nb o d yf a tc o m p o s i t i o ni no b e s er a t s † (mean values with their standard errors, n = 12).
Control groups LWDH-treated groups
OR OP T1A T1B T1C
Mean SE Mean SE Mean SE Mean SE Mean SE
Epididymal (g) 5.54 0.29 9.70 0.75 9.60 0.65 8.56 0.48 6.96∗ 0.51
Perirenal (g) 6.79 1.32 11.00 1.39 10.62 1.23 8.84 0.80 7.91∗ 0.79
Omental (g) 7.71 1.29 11.21 0.85 12.46 0.81 10.64 0.43 8.72∗ 0.67
Total (g) 19.58 2.16 31.92 2.49 32.67 2.33 28.03 1.43 23.59∗ 1.68
LWDH: Liuwei Dihuang; OR: obesity-resistant normal control group; OP: obesity-prone positive control group; T1A: 500mg/kg/d LWDH group; T1B:
1500mg/kg/dLWDH group; T1C: 3500mg/kg/dLWDH group.
∗Mean values within a row were signiﬁcantly diﬀerent from OP (pair-wise comparisons using the least squares means test; P<0.05).
†The change in body fat mass in obese rats treated with total daily dosages of 500, 1500, or 3500mg/kg BWLWDH is given.
Table 2: Eﬀect of LWDH on weekly food intake in obese rats† (mean values with their standard errors, n = 12).
Control groups LWDH-treated groups
OR OP T1A T1B T1C
Mean SE Mean SE Mean SE Mean SE Mean SE
Week 1 (g) 13.88 0.79 14.57 0.62 15.42 0.62 15.39 0.44 15.17 0.40
Week 2 (g) 14.43 0.61 15.34 1.88 15.13 0.36 14.14 0.35 13.08∗ 0.61
Week 3 (g) 12.91 0.63 14.41 0.55 15.07 0.44 12.55∗ 0.54 11.92∗ 0.52
Week 4 (g) 13.35 0.71 15.68 0.89 15.03 0.51 13.68∗ 0.62 13.11∗ 0.36
Week 5 (g) 13.67 0.49 17.07 0.38 16.31 0.55 15.11 0.89 15.93∗ 0.54
Week 6 (g) 14.39 0.64 14.36 0.64 14.31 0.73 13.75 0.45 13.40∗ 0.42
Week 7 (g) 14.76 0.65 15.81 0.78 15.78 0.96 14.68 0.85 13.58∗ 0.51
Week 8 (g) 12.46 0.86 14.16 0.90 13.59 0.52 13.14 0.51 12.29∗ 0.51
Week 9 (g) 12.86 1.02 13.68 0.65 14.48 0.64 13.12 0.76 13.25∗ 0.63
Week 10 (g) 12.96 0.84 14.42 0.73 14.15 0.58 15.10 0.77 13.72∗ 0.65
LWDH: Liuwei Dihuang; OR: obesity-resistant normal control group; OP: obesity-prone positive control group; T1A: 500mg/kg/dLWDH group; T1B:
1500mg/kg/dLWDH group; T1C: 3500mg/kg/dLWDH group.
∗Mean values within a row were signiﬁcantly diﬀerent from OP (pair-wise comparisons using the least squares means test; P<0.05).
†The change in weekly food intake in obese rats treated with total daily dosages of 500, 1500, or 3500mg/kg BWLWDH is given.
serum NEFA levels (P = 0.14) when compared to the OP
control. The T1A group did not show any eﬀect.
3.6. LWDH Signiﬁcantly Lowered Serum Insulin and Leptin
in Obese Rats. Serum levels of insulin and leptin were
quantiﬁed at the end of the treatment period. In response to
the T1B and T1C treatments, serum insulin and leptin levels
were signiﬁcantly reduced (P<0.05) (Figure 4).
3.7. Serum Liver Enzyme Proﬁle in Obese Rats in Response to
LWDH Treatment. To assess the safety or potential toxicity
of the LWDH concentrated pills, liver function tests were
performed by measuring the serum levels of a suite of liver
enzymes, including AST, ALT, ALP, and GGT. The results
indicated that none of the 3LWDH doses altered the serum
levels of AST, ALT, or GGT (Table 3). Noteworthy, serum
ALP levels were signiﬁcantly reduced (P<0.05) in the T1C
group compared to the OP control.
4. Discussion
Theresultsofthepresentstudyhavehighlightedthepotential
body weight-lowering capability of LWDH. When rats were
treated with the high LWDH dose, body weights were low-
ered signiﬁcantly after 7 weeks of treatment, and this eﬀect
was retained throughout the remainder of the treatment
period. In line with the observed body weight reductions,
epididymal, perirenal, and omental fat depots were also
signiﬁcantly lowered. The high LWDH dose also reduced
serum TG and NEFA levels. Furthermore, the medium and
high LWDH doses decreased serum insulin and leptin levels
in a dose-dependent manner. These parameters are all highly
related to obesity, and a reduction in any one is, in turn,
beneﬁcial to weight control and the mitigation of obesity-
related complications [24–26].
Overweight and obesity have emerged and continue to
grow as new threats to the quality of human life. Accumu-
lating evidence, however, suggests that a modest weight
reduction of 5–10% is suﬃcient to improve, or even abolish,
several obesity-related complications [4, 27]. In the present
study, LWDH reduced body weight in obese rats by over
8% after 7 weeks of treatment when provided at a dose of
3500mg/kg/d. The 1500mg/kg/d dose showed a tendency
towardsweightlossbutdidnotreachastatisticallysigniﬁcant
level. A similar and dose-dependent reduction was observed
in regards to food intake, which signiﬁcantly correlated withEvidence-Based Complementary and Alternative Medicine 5
Table 3: Serum liver enzyme proﬁle in obese rats in response to LWDH treatment† (mean values with their standard errors, n = 12).
Control groups LWDH-treated groups
OR OP T1A T1B T1C
Mean SE Mean SE Mean SE Mean SE Mean SE
AST (U/L) 197.54 25.14 178.79 9.67 180.46 12.09 187.25 13.53 199.46 12.77
ALT (U/L) 38.00 1.83 46.04 1.95 44.88 1.51 41.88 1.16 44.45 2.06
ALP (U/L) 168.21 13.15 295.75 1.69 269.38 6.16 271.29 15.58 252.63∗ 11.68
GGT (U/L) 8.71 0.14 9.12 0.25 8.83 0.33 9.25 0.23 8.77 0.42
LWDH: Liuwei Dihuang; OR: obesity-resistant normal control group; OP: obesity-prone positive control group; T1A: 500mg/kg/dLWDH group; T1B:
1500mg/kg/dLWDH group; T1C: 3500mg/kg/dLWDH group.
∗Mean values within a row were signiﬁcantly diﬀerent from OP (pair-wise comparisons using the least squares means test; P<0.05).
†The change in serum liver enzyme proﬁles in obese rats treated with total daily dosages of 500, 1500, or 3500mg/kg BWLWDH is given.
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Figure 3: LWDH signiﬁcantly lowered serum nonesteriﬁed fatty
acids in obese rats. OR: obesity-resistant normal control; OP:
obesity-prone positive control; T1A, T1B, and T1C represent the
3 obesity-prone groups treated by twice daily oral gavage with
total daily dosages of 500, 1500, or 3500mg/kg BW of the LWDH
herbal formulation, respectively. All animals were fed a high-fat
diet (AIN-93G diet modiﬁed to contain 60% energy from fat
(lard:sunﬂower oil (96:4,wt/wt)). Data were analyzed by one-way
ANOVA. Diﬀerences between treatment means were determined by
pair-wise comparisons using the least squares means test, with P<
0.05indicatingstatisticalsigniﬁcance.Resultsarepresentedasmean
values with their standard errors (n = 12). ∗Diﬀered signiﬁcantly
from OP (P<0.05).
weight changes, suggesting that the observed body weight
reductions following LWDH treatment might, at least in
part, be a result of decreased energy consumption. Food
intake is inﬂuenced not only by nutritional status, but also
by various palatability cues, including taste and smell [28,
29]. In the current study, LWDH was administered by oral
gavage and thus should not have had any adverse eﬀects
on food taste. In addition, food intake was monitored on a
daily basis throughout the entire study, and no signiﬁcant
decreases were observed throughout the ﬁrst treatment
week. If LWDH had an aversive taste, food intake would
have been decreased immediately upon commencement of
the treatment. As an aversion to taste was not seen, it
is thought that LWDH might have inhibited appetite or
induced satiety through interaction with the gut-brain axis,
but this requires further investigation. Noteworthy is the
fact that LWDH was administered in the form of a partially
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Figure 4: LWDH signiﬁcantly lowered serum insulin and leptin
in obese rats. OR: obesity-resistant normal control; OP: obesity-
prone positive control; T1A, T1B, and T1C represent the 3 obesity-
prone groups treated by twice daily oral gavage with total daily
dosages of 500, 1500, or 3500mg/kg BW of the LWDH herbal
formulation, respectively. All animals were fed a high-fat diet (AIN-
93G diet modiﬁed to contain 60% energy from fat (lard:sunﬂower
oil (96:4, wt/wt)). Data were analyzed by one-way ANOVA.
Diﬀerencesbetweentreatmentmeansweredeterminedbypair-wise
comparisons using the least squares means test, with P<0.05
indicating statistical signiﬁcance. Results are presented as mean
values with their standard errors (n = 12). ∗Diﬀered signiﬁcantly
from OP (P<0.05).
reﬁned concentrated pill, which explains the high doses
employed in the present study. The high dosage of LWDH
was similar to a diabetes study in rats [22] and higher than
the human dosage used for general health promotion [30].
The dosage for weight management in humans has not yet
been documented. The current dosage can be signiﬁcantly
reduced when administered in the form of an extract or
fraction and following dosage optimization. Furthermore,
with respect to translation into the potential for human
use, thrice daily dosing is recommended in TCM for general
healthpromotion.Studieshaveshowntwicedailyoraldosing
regimes to be equal [31]o rs u p e r i o r[ 32]t oo n c ed a i l y
regimes in terms of eﬃcacy and safety.
Hyperlipidemia and increased circulating free fatty acids
are generally associated with obesity [26]. In the present
study, the high LWDH dose signiﬁcantly lowered blood TG6 Evidence-Based Complementary and Alternative Medicine
and NEFA levels, in line with the observed body weight
reductions, and showed a tendency towards lowering T-
C levels. It is well known that in addition to elevated
circulating cholesterol levels, increased blood TG levels
are an independent risk factor for the development of
atherosclerosis and CVD [25]. Metabolically, fatty acids
and TG are interrelated, and their blood levels change
in proportion to one another [33]. Elevated circulating
levels of TG and NEFA are commonly observed in obese
individuals, resulting from increased fat mobilization from
adipose tissues [34, 35], and are further elevated with the
onset of insulin and/or leptin resistance [36]. Improvement
of insulin and/or leptin sensitivity stimulates fatty acid
oxidation, resulting in a reduction in circulating TG and
N E F Al e v e l s[ 37]. The reductions in circulating TG and
NEFA levels might be a consequence of LWDH-mediated
body weight reduction, resulting in improved insulin and
leptin sensitivity and thus fatty acid oxidation, in addition
to reduced fat mobilization from adipose tissues and a
consequential decrease in circulating NEFA levels following
weight loss.
Energy homeostasis requires a highly integrated neuro-
humoral control system involving several hormones, includ-
ingleptinandinsulin[37,38].Leptinandinsulinaresecreted
in direct proportion to adipose tissue mass [37]. In the
obese state, an increase in adipose tissue mass leads to
increased secretion of insulin and leptin into the circulation
[38], often resulting in the development of hyperinsulinemia
and hyperleptinemia, respectively [39, 40]. Normally, these
hormones can relay information about peripheral fat stores
to the brain and eﬀectively modulate food intake and energy
expenditure [12, 41], through inhibition and activation of
anabolic and catabolic pathways, respectively [39]. However,
in the obese state, insensitivity to the antiobesity eﬀects
of these regulatory hormones often develops [13, 14]. In
the present study, the medium and high LWDH doses
signiﬁcantlyreducedbloodlevelsofinsulinandleptin,which
were correlated with the observed weight changes, especially
in response to the high dose. The reduced levels of both
hormones in the serum could be a result of the observed
weight reduction by LWDH and subsequent improvements
of their sensitivity. Nevertheless, it is not possible to exclude
the prospect that LWDH also directly aﬀected insulin and
leptin sensitivity, independent of weight changes.
As LWDH is an herbal formulation, it was also of
interest to determine if any toxic eﬀects may be linked to
the application of this product. Rats were monitored on a
daily basis, and no abnormal behaviours or activities were
noted throughout the entire study period. In addition, liver
functiontestswhichareusedroutinelytodetectthepotential
toxicity of a product [42]w e r ec o n d u c t e d .A n a l y s i so f4
liver enzymes that are generally used in clinical testing did
not reveal any toxic eﬀect of LWDH under the current
experimental conditions. Furthermore, blood concentra-
tions of liver enzymes are indicative of a tendency towards
the development of obesity [43]. Decreased concentrations
of these enzymes in obese individuals reﬂect improved
insulin sensitivity and reduced fat accumulation in the liver
[43], whereas elevated levels represent an increased risk
for the development of T2DM and CVD [44, 45]. The
observed reductions in serum ALP levels in response to the
high LWDH dose might be indicative of improved insulin
sensitivity,inlinewiththesigniﬁcantlyreducedbloodinsulin
andleptinlevels,inaddition tothepotentialimprovementof
liver function following weight loss.
In conclusion, the present study has demonstrated the
antiobesity eﬀects of LWDH in obese rats, without any
observable toxic eﬀects as evaluated by liver function testing.
Moreover, LWDH improved blood lipid proﬁles, including
NEFA, and lowered blood leptin and insulin levels, which
may be indicative of an improvement in insulin and leptin
sensitivity. The results presented herein have shed light
on the potential for the development of LWDH as a
natural product for the management of obesity and its
related complications. These ﬁndings could be related to the
regulation of LWDH on appetite, which awaits further inves-
tigation.
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